Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT-IPF: TTI-101 in Idiopathic Pulmonary Fibrosis
NCT05671835Phase 2Completed
- Sponsor
- Tvardi Therapeutics
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tti-101 in idiopathic pulmonary fibrosis (IPF), sponsored by Tvardi Therapeutics. Started May 2023; status: completed.
02
Drugs
tti-101
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05671835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671835.